Pregled bibliografske jedinice broj: 1258208
Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization
Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization // British journal of clinical pharmacology, 88 (2022), 12; 5060-5063 doi:10.1111/bcp.15548 (međunarodna recenzija, komentar, stručni)
CROSBI ID: 1258208 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Spotlight commentary: Navigating between financial
risks and improved treatment outcomes with immune
checkpoint inhibitors in cancer patients: The need
for biomarker identification and dose optimization
Autori
Likić, Robert ; Dear, James W. ; Lewis, Lionel D.
Izvornik
British journal of clinical pharmacology (0306-5251) 88
(2022), 12;
5060-5063
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, komentar, stručni
Ključne riječi
Checkpoint inhibitors ; outcomes ; biomarkers ; treatment optimization
Sažetak
U radu se raspravlj ao financijskim rizicima i potrebi optimizacije terapije checkpoint inhibitorima putem identifikacije biomarkera i titriranja terapijske doze.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Robert Likić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
